3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Surgical Wound Infection
4
Colorectal Neoplasms
4
Neoplasms
3
Sepsis
2
Pancreatic Neoplasms
2
Leukemia, Myeloid, Acute
2
Febrile Neutropenia
2
Triple Negative Breast Neoplasms
1
Solitary Pulmonary Nodule
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Fistula
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Multiple Pulmonary Nodules
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Inflammation
1
Infections
1
Glioblastoma
1
Fever
1
Exanthema
1
Emergencies
1
Duodenal Neoplasms
1
Discitis
1
Diarrhea
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
58
Cisplatin
41
Capecitabine
27
Oxaliplatin
25
durvalumab
16
Fluorouracil
16
Leucovorin
15
S 1 (combination)
11
lenvatinib
10
Nivolumab
10
Irinotecan
10
pembrolizumab
8
apatinib
8
Immune Checkpoint Inhibitors
7
130-nm albumin-bound paclitaxel
7
tremelimumab
6
Bevacizumab
6
camrelizumab
5
Trastuzumab
5
Drug Therapy
5
Blood Specimen Collection
5
Albumin-Bound Paclitaxel
5
tislelizumab
4
irinotecan sucrosofate
4
Taxes
4
Liquid Biopsy
4
Folfox protocol
4
toripalimab
3
surufatinib
3
gemcitabine-oxaliplatin regimen
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Biliary Tract Neoplasms
×
Anti-Bacterial Agents
×
Clear all
NCT03631173
2026-04-28
MINIMUM
Oslo University Hospital
Phase NA
Active not recruiting
201 enrolled